Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.8 EUR | -10.00% | +18.42% | +65.14% |
May. 16 | GeNeuro SA Announces Last Patient Last Visit in Its Post-Covid Trial and Confirms Top-Line Results by End of June 2024 | CI |
Mar. 20 | Geneuro SA Announces Appointments of Board of Directors | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+65.14% | 64.29M | |
+42.52% | 54.04B | |
+43.57% | 41.96B | |
-1.26% | 41.92B | |
-7.59% | 28.35B | |
+11.71% | 26.35B | |
-22.32% | 19B | |
+7.90% | 13B | |
+28.97% | 12.28B | |
+25.59% | 12.19B |
- Stock Market
- Equities
- GNRO Stock
- News GeNeuro SA
- GeNeuro Begins Recruitment for Trial to Assess Temelimab's Efficacy as Therapy for Long COVID-19